At the world’s largest oncology meeting, which concluded this week, researchers presented new findings that suggest that the timing, combination and duration of immunotherapy, as well as the order in which drugs are given, may have an even greater impact on skin cancer patient outcomes than previously understood.
Of Interest
Genetic mutation identified as key factor in immunotherapy resistance for melanoma
Tests in 1,225 patients with the most deadly form of skin cancer reveal for the first time a genetic trait among most of those who did not respond to the latest cancer treatments, known as immune checkpoint inhibitors.
IMA203 Demonstrates Early Promise in PD-1–Refractory Metastatic Melanoma
IMA203 showed acceptable tolerability and early clinical activity in PD-1–refractory metastatic melanoma patients, with no grade 5 adverse events observed.
Inherited Genetic Differences in Cell Energy Centers Predict Resistance to Therapy for Deadly Skin Cancer
Results from a new study help resolve the decade-long mystery of why many patients with the deadliest form of skin cancer do not respond to the latest cancer treatments.